Discounted Cash Flow (DCF) Analysis Levered
Interpace Biosciences, Inc. (IDXG)
$2.44
-0.15 (-5.97%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 21.90 | 24.08 | 32.40 | 41.31 | 31.84 | 35.75 | 40.13 | 45.06 | 50.59 | 56.80 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -8.67 | -18.96 | -13.98 | -8.72 | -7.69 | -14.78 | -16.60 | -18.63 | -20.92 | -23.49 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.45 | -0.13 | -1.57 | -0.35 | -0.32 | -0.67 | -0.75 | -0.84 | -0.94 | -1.06 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -9.12 | -19.09 | -15.55 | -9.07 | -8.01 | -15.45 | -17.34 | -19.47 | -21.86 | -24.55 |
Weighted Average Cost Of Capital
| Share price | $ 2.44 |
|---|---|
| Beta | 0.781 |
| Diluted Shares Outstanding | 4.13 |
| Cost of Debt | |
| Tax Rate | -0.13 |
| After-tax Cost of Debt | 8.55% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 7.380 |
| Total Debt | 1.85 |
| Total Equity | 10.09 |
| Total Capital | 11.94 |
| Debt Weighting | 15.48 |
| Equity Weighting | 84.52 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 21.90 | 24.08 | 32.40 | 41.31 | 31.84 | 35.75 | 40.13 | 45.06 | 50.59 | 56.80 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.67 | -18.96 | -13.98 | -8.72 | -7.69 | -14.78 | -16.60 | -18.63 | -20.92 | -23.49 |
| Capital Expenditure | -0.45 | -0.13 | -1.57 | -0.35 | -0.32 | -0.67 | -0.75 | -0.84 | -0.94 | -1.06 |
| Free Cash Flow | -9.12 | -19.09 | -15.55 | -9.07 | -8.01 | -15.45 | -17.34 | -19.47 | -21.86 | -24.55 |
| WACC | ||||||||||
| PV LFCF | -14.36 | -14.99 | -15.65 | -16.33 | -17.05 | |||||
| SUM PV LFCF | -78.39 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.56 |
| Free cash flow (t + 1) | -25.04 |
| Terminal Value | -450.33 |
| Present Value of Terminal Value | -312.81 |
Intrinsic Value
| Enterprise Value | -391.20 |
|---|---|
| Net Debt | -2.98 |
| Equity Value | -388.22 |
| Shares Outstanding | 4.13 |
| Equity Value Per Share | -93.89 |